Drugs / Lucitanib
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03260179 | Aug 2017 → Jan 2019 | colorectal cancer | Haihe Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03117101 | Mar 2014 → Sep 2016 | cancer | Haihe Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT04151563 | Apr 2021 → Dec 2023 | non-small cell lung carcinoma | Bristol-Myers Squibb | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04042116 | Jul 2019 → Jul 2023 | female reproductive organ cancer | Clovis Oncology, Inc. | Suspended | No outcome recorded |
| Phase 1/2 | NCT03992131 | Jun 2019 → Mar 2022 | ovarian cancer, triple-negative breast carcinoma, urothelial carcinoma | pharmaand GmbH | Terminated | No outcome recorded |
| Phase 1/2 | NCT01283945 | Jul 2010 → Sep 2016 | cancer | Servier | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07824505 | Aug 2018 → Sep 2021 | thymic carcinoma | Haihe Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02747797 | Apr 2017 → Apr 2021 | — | Teresa Helsten, MD | Withdrawn | No outcome recorded |
| Phase 2 | NCT02202746 | Sep 2014 → Jan 2017 | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer, triple-negative breast carcinoma | Clovis Oncology, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02109016 | Apr 2014 → Apr 2016 | non-small cell squamous lung carcinoma, small cell lung carcinoma | Clovis Oncology, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02053636 | Dec 2013 → Mar 2017 | breast cancer | Servier | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04254471 | Nov 2019 → May 2022 | small cell lung carcinoma | Haihe Biopharma Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-28 | Haihe Biopharma Co., Ltd. | Results 海和药物宣布2项研究亮相2024年中国临床肿瘤学会（CSCO）学术年会口头报告 haihepharma.com ↗
疗效结果显示：研究者评估的德立替尼组mPFS为6.6个月，安慰剂组为1.9个月，mPFS延长4.7个月（p=0.0306，HR=0.53），疾病进展或死亡风险降低47%。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-28 | Haihe Biopharma Co., Ltd. | 海和药物宣布2项研究亮相2024年中国临床肿瘤学会（CSCO）学术年会口头报告 haihepharma.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lucitanib | “Lucitanib is a novel multi-target inhibitor of FGFR1-3, VEGFR 1-3, and PDGFR α/β.” PMID 35445718 ↗ Jun 2022 |
| Known as | AL3810 | “A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma.” PMID 35445718 ↗ Jun 2022 |
| Known as | CO-3810 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2220486 ↗ |
| Known as | E-3810 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2220486 ↗ |
| Known as | S 80881 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2220486 ↗ |
| Action | Inhibit | “Lucitanib is a novel dual-targeted small molecule inhibitor of VEGFR1, 2, 3 and FGFR1” NCT01283945 ↗1“Fibroblast growth factor receptor 2 inhibitor” CHEMBL2220486 ↗ |
| Modality | Small molecule | “Lucitanib is a novel dual-targeted small molecule inhibitor of VEGFR1, 2, 3 and FGFR1” NCT01283945 ↗ |
| Route | Oral | “the Maximum Tolerated Dose (MTD) of Lucitanib administered orally, once daily” NCT01283945 ↗ |
| Target | FGFR1 | “Lucitanib is a novel dual-targeted small molecule inhibitor of VEGFR1, 2, 3 and FGFR1” NCT01283945 ↗ |
| Target | FGFR2 | “Fibroblast growth factor receptor 2 inhibitor” CHEMBL2220486 ↗ |